Canagliflozin vs Empagliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Canagliflozin · Invokana
Marketed by Johnson & Johnson and partners
NCT01032629 · Phase 3 · completed
The trial randomized 4,330 participants to canagliflozin or placebo with quadruple masking and used a hard clinical primary endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Results were discordant across the prespecified comparisons: the 300-mg dose met the endpoint comparison, while the 100-mg dose and combined canagliflozin analysis did not.
Next expected readout: December 2026 · NCT05427084 (registry estimate)
Reported efficacy
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 (Baseline (Day 1) and Week 26); Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) (Baseline (Day 1) up to 30 days post last dose at Week 52 (up to Week 56)): Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002). (met)
Result source: NCT03170518
Empagliflozin · Jardiance
Marketed by Boehringer Ingelheim and partners
NCT01131676 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial enrolling 7,064 participants. The hard clinical primary endpoint was met: pooled empagliflozin was non-inferior and also statistically superior to placebo for 3-point MACE, with 10.5% versus 12.1% of participants experiencing an event (HR 0.86; p=0.0382).
Next expected readout: November 2026 · NCT05057806 (registry estimate)
Reported efficacy
Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1% (met)
Result source: NCT01131676
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Canagliflozin | Empagliflozin |
|---|---|---|
| HbA1c, change | -0.4% vs 0.4%−0.8 vs placeboNCT0317051841 other results
| -0.7% vs -0.2%−0.5 vs placeboNCT0115960032 other results
|
| Body weight, change (kg) | -2.9 vs -0.8−2.1 vs placeboNCT006422788 other results
| -2.1 vs -0.4−1.7 vs placeboNCT0115960018 other results
|
| HbA1c below 7% | 42.8% vs 43%vs Metformin XRNCT018093276 other results
| 34.6% vs 24.5%+10.1 vs placeboNCT034295433 other results
|
| Fasting plasma glucose, change | -0.6 vs 0.2−0.7 vs placeboNCT0103262934 other results
| -1.8 vs 0.3−2.1 vs placeboNCT0173478511 other results
|
| 3-point MACE (% with event) | —Not posted · NCT04304261 | 10.4% vs 12.1%−1.7 vs placeboNCT011316762 other results
|
HbA1c, change
- Canagliflozin
- -0.4% vs 0.4%−0.8 vs placeboNCT03170518
41 other results
- -0.7% vs -0.0% NCT01106651
- -0.4% vs -0.0% NCT01064414
- -1.0% vs -0.3% NCT01106690
- -1.1% vs -0.1% NCT01106625
- -1.0% vs 0.1% NCT01081834
- -1.1% vs -0.5% NCT01381900
- -0.6% vs -0.0% NCT01106651
- -0.3% vs -0.0% NCT01064414
- -0.9% vs -0.3% NCT01106690
- -0.8% vs -0.1% NCT01106625
- -0.8% vs 0.1% NCT01081834
- -1.0% vs -0.5% NCT01381900
- -1.0% vs -0.1% NCT02354235
- -0.9% vs -0.8% NCT00968812
- -1.0% vs -0.7% NCT01137812
- -1.4% vs -1.3% NCT01809327
- -0.9% vs -0.8% NCT01106677
- -0.8% vs -0.8% NCT00968812
- -1.4% vs -1.3% NCT01809327
- -0.8% vs -0.8% NCT01106677
- -1.8% vs -1.3% NCT01809327
- -1.8% vs -1.3% NCT01809327
- -0.3% vs 0.0% NCT01032629
- -0.3% vs 0.0% NCT01032629
- -0.3% vs 0.7% NCT03170518
- -0.6% vs 0.1% NCT03170518
- -0.9% vs -0.7% NCT01106677
- -0.7% vs -0.6% NCT00968812
- -0.7% vs -0.7% NCT01106677
- -0.7% vs -0.6% NCT00968812
- -0.9% vs -0.2% NCT00642278
- -0.8% vs -0.2% NCT00642278
- -0.9% vs -0.2% NCT00642278
- -0.7% vs -0.2% NCT00642278
- -0.6% vs -0.0% NCT01340664
- -0.5% vs -0.0% NCT01340664
- -0.8% vs -0.2% NCT00642278
- -0.9% vs -0.0% NCT02025907
- -1.0% vs 0.1% NCT02220920
- -0.9% vs -1.1% NCT02622113
- 7.8% vs 8.3% NCT02964585
- Empagliflozin
- -0.7% vs -0.2%−0.5 vs placeboNCT01159600
32 other results
- -0.8% vs -0.2% NCT01159600
- -0.8% vs -0.2% NCT01159600
- -0.8% vs -0.2% NCT01159600
- -1.1% vs -0.1% NCT04233801
- -0.7% vs 0.1% NCT02182830
- -2.8% vs -0.2% NCT01159600
- -2.5% vs -0.2% NCT01159600
- -1.1% vs -0.1% NCT04233801
- -0.9% vs -0.3% NCT02489968
- -0.6% vs 0.1% NCT01734785
- -0.9% vs -0.3% NCT02489968
- -0.9% vs 0.2% NCT02453555
- -0.7% vs 0.1% NCT01734785
- -1.4% vs -1.8% NCT01719003
- -2.1% vs -1.8% NCT01719003
- -0.2% vs 0.3% NCT03429543
- -1.4% vs -1.8% NCT01719003
- -1.9% vs -1.8% NCT01719003
- -2.1% vs -1.8% NCT01719003
- -2.0% vs -1.8% NCT01719003
- -0.5% vs 0.3% NCT03429543
- 0.1% vs 0.3% NCT03429543
- -1.1% vs 0.1% NCT02453555
- -1.1% vs -0.0% NCT02453555
- -0.2% vs 0.1% NCT03429543
- -0.6% vs -0.2% NCT01649297
- -0.7% vs -0.2% NCT01649297
- -0.8% vs -0.2% NCT01649297
- -0.7% vs -0.1% NCT04531462
- -0.9% vs 0% NCT02589639
- -1% vs 0% NCT02589639
- -0.7% vs -0.2% NCT01649297
Body weight, change (kg)
- Canagliflozin
- -2.9 vs -0.8−2.1 vs placeboNCT00642278
8 other results
- -1.5 vs 0.1 NCT01939496
- -2.3 vs -0.8 NCT00642278
- -1.0 vs 0.1 NCT01939496
- -2.9 vs -0.8 NCT00642278
- -2.3 vs -0.8 NCT00642278
- -2.0 vs -0.8 NCT00642278
- -3.5 vs -1.9 NCT02324842
- -6 vs -1.9 NCT02324842
- Empagliflozin
- -2.1 vs -0.4−1.7 vs placeboNCT01159600
18 other results
- -2.2 vs -0.4 NCT01159600
- -2.5 vs -0.4 NCT01159600
- -2.4 vs -0.4 NCT01159600
- -0.8 vs -0.0 NCT03429543
- -2.0 vs 0.0 NCT04233801
- -2.2 vs -1.0 NCT02182830
- -1.3 vs -0.4 NCT01159600
- -1.3 vs -0.4 NCT01159600
- -1.3 vs 0.0 NCT04233801
- -2.5 vs -0.3 NCT01734785
- -3.1 vs -0.3 NCT01734785
- 1.3 vs -0.0 NCT03429543
- -2.4 vs -1.3 NCT01719003
- -2.4 vs -1.3 NCT01719003
- -3.8 vs -1.3 NCT01719003
- -3.0 vs -1.3 NCT01719003
- -3.5 vs -1.3 NCT01719003
- -2.8 vs -1.3 NCT01719003
HbA1c below 7%
- Canagliflozin
- 42.8% vs 43%vs Metformin XRNCT01809327
6 other results
- 38.8% vs 43% NCT01809327
- 56.8% vs 43% NCT01809327
- 49.6% vs 43% NCT01809327
- 57.1% vs 31.5% NCT01340664
- 47.8% vs 31.5% NCT01340664
- 32.3% vs 12.2% NCT02025907
- Empagliflozin
- 34.6% vs 24.5%+10.1 vs placeboNCT03429543
3 other results
- 16.7% vs 8.2% NCT04233801
- 30.1% vs 8.2% NCT04233801
- 66.7% vs 24.5% NCT03429543
Fasting plasma glucose, change
- Canagliflozin
- -0.6 vs 0.2−0.7 vs placeboNCT01032629
34 other results
- -0.4 vs 0.2 NCT01032629
- -1.1 vs 0.4 NCT01106651
- -0.7 vs 0.0 NCT01064414
- -1.8 vs 0.1 NCT01106690
- -1.7 vs 0.2 NCT01106625
- -1.9 vs 0.5 NCT01081834
- -0.1 vs -0.0 NCT01381900
- -1 vs 0.4 NCT01106651
- -0.8 vs 0.0 NCT01064414
- -1.5 vs 0.1 NCT01106690
- -1.0 vs 0.2 NCT01106625
- -1.5 vs 0.5 NCT01081834
- -0.1 vs -0.0 NCT01381900
- -1.9 vs 0.2 NCT02354235
- -2.1 vs -1.1 NCT01106677
- -1.9 vs -1.0 NCT01106677
- -1.7 vs -0.3 NCT01137812
- -1.5 vs -1.1 NCT01106677
- -1.4 vs -1.0 NCT01106677
- 9.7 vs 9.8 NCT02324842
- 10.0 vs 9.8 NCT02324842
- -1.4 vs 0.2 NCT00642278
- -1.3 vs -0.4 NCT01939496
- -1.4 vs 0.2 NCT00642278
- -0.0 vs -0.4 NCT01939496
- -1.3 vs 0.2 NCT00642278
- -1.5 vs 0.2 NCT00642278
- -0.9 vs 0.5 NCT01340664
- -0.9 vs 0.5 NCT01340664
- -0.9 vs 0.2 NCT00642278
- -1.6 vs -0.1 NCT02025907
- -1.9 vs -0.1 NCT02220920
- -1.8 vs -1.8 NCT02622113
- 7.9 vs 8.8 NCT02964585
- Empagliflozin
- -1.8 vs 0.3−2.1 vs placeboNCT01734785
11 other results
- -1.5 vs 0.3 NCT01734785
- -1.8 vs -1.8 NCT01719003
- -1.6 vs -1.8 NCT01719003
- -2.8 vs -1.8 NCT01719003
- -2.4 vs -1.8 NCT01719003
- -2.6 vs -1.8 NCT01719003
- -2.5 vs -1.8 NCT01719003
- -1.0 vs -0.0 NCT01649297
- -1.3 vs -0.0 NCT01649297
- -1.5 vs -0.0 NCT01649297
- -1.2 vs -0.0 NCT01649297
3-point MACE (% with event)
- Canagliflozin
- —Not posted · NCT04304261
- Empagliflozin
- 10.4% vs 12.1%−1.7 vs placeboNCT01131676
2 other results
- 10.5% vs 12.1% NCT01131676
- 10.5% vs 12.1% NCT01131676
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
8 other shared endpoints and safety
Coverage. Canagliflozin: 12 of 12 rows · Empagliflozin: 12 of 12 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Canagliflozin Rows use multiple source trials | Empagliflozin Rows use multiple source trials |
|---|---|---|
| Ambulatory DBP absolute change · mmHg | -3.27 vs -0.26 placebo mmHg @ 6wk300 mga,b,c,d,e NCT01939496 · Phase 4 · registry result, not featured evidence show 1 more dose-2.18 vs -0.26 placebo mmHg @ 6wk100 mg NCT01939496 · Phase 4 · registry result, not featured evidence | -6.38 vs -1.48 placebo mmHg @ 24wk10 mg-25 mgb,c,d,e NCT02182830 · Phase 3 · registry result, not featured evidence |
| Ambulatory SBP absolute change · mmHg | -7.31 vs -1.26 placebo mmHg @ 6wk300 mga,b,c,d,e NCT01939496 · Phase 4 · registry result, not featured evidence show 1 more dose-4.78 vs -1.26 placebo mmHg @ 6wk100 mg NCT01939496 · Phase 4 · registry result, not featured evidence | -10.33 vs -1.94 placebo mmHg @ 24wk10 mg-25 mgb,c,d,e NCT02182830 · Phase 3 · registry result, not featured evidence |
| Body Fat Mass absolute change · kg | -2.38 vs -0.28 placebo kg @ 26wk300 mga,f,c,d,g NCT01106651 · Phase 3 · registry result, not featured evidence show 1 more dose-1.87 vs -0.28 placebo kg @ 26wk100 mg NCT01106651 · Phase 3 · registry result, not featured evidence | -1.77 vs 0.08 placebo kg @ 52wk10 mgf,c,d,g NCT04531462 · Phase 4 · registry result, not featured evidence |
| Fasting Plasma Glucose Change mg/dL absolute change · mg | -11.5 vs 15.3 placebo mg @ 26wk100/300 mgh,d NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 | -19.48 vs 15.7 placebo mg @ 26wk10 mg, 25 mga,h,d NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 show 1 more dose-18.45 vs 15.7 placebo mg @ 26wk10 mg, 25 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 |
| HbA1c absolute change · percentage points No placebo or comparator arm | -0.7% (n=71) @ 52wkc,d NCT02227849 · Phase 4 · registry result, not featured evidence · combination 1 other source trial-0.99% (n=153) @ 52wk NCT02220907 · Phase 3 · registry result, not featured evidence · combination | -0.55% (n=32) @ 52wk10 mga,c,d NCT02589626 · Phase 4 · registry result, not featured evidence show 1 more dose-0.77% (n=33) @ 52wk25 mg NCT02589626 · Phase 4 · registry result, not featured evidence |
| SBP absolute change · mmHg | -4.65 vs -0.66 Sitagliptin mmHg @ 52wk300 mga,c,d,i NCT01106677 · Phase 3 · registry result, not featured evidence show 1 more dose-3.53 vs -0.66 Sitagliptin mmHg @ 52wk100 mg NCT01106677 · Phase 3 · registry result, not featured evidence | -5.56 vs -1.95 placebo mmHg @ 24wk10 mga,c,d,i NCT04233801 · Phase 3 · registry result, not featured evidence show 1 more dose-2.96 vs -1.95 placebo mmHg @ 24wk25 mg NCT04233801 · Phase 3 · registry result, not featured evidence |
| Seated DBP absolute change · mmHg | -0.1 vs -0.1 placebo mmHg @ 26wk100/300 mgh,d NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 | 0.78 vs 0.76 placebo mmHg @ 26wk10 mg, 25 mga,h,d NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 show 1 more dose-3.2 vs 0.76 placebo mmHg @ 26wk10 mg, 25 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 |
| Seated SBP absolute change · mmHg | 0.7 vs 1.4 placebo mmHg @ 26wk100/300 mgh,d NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 | -0.12 vs 1.3 placebo mmHg @ 26wk10 mg, 25 mga,h,d NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 show 1 more dose2.63 vs 1.3 placebo mmHg @ 26wk10 mg, 25 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 |
| Dropout rate | 6.1%300 mgj NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 72 more results7%100 mg NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 33.4%300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 29%100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 17.6%300 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 10.4%100 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 0.7%100 mg NCT02065791 · Phase 3 0% NCT02964585 · Phase 4 · registry result, not featured evidence —300 mg NCT03267576 · Phase 4 · registry result, not featured evidence 0% NCT02920918 · Phase 4 · registry result, not featured evidence 1.2% NCT01989754 · Phase 4 · registry result, not featured evidence 13.2% NCT02622113 · Phase 4 · registry result, not featured evidence · combination 11.3% NCT02227849 · Phase 4 · registry result, not featured evidence · combination 11.1% NCT02025907 · Phase 4 · registry result, not featured evidence 3.9% NCT02220920 · Phase 4 · registry result, not featured evidence · combination 3.6%300 mg NCT01939496 · Phase 4 · registry result, not featured evidence 5.3%100 mg NCT01939496 · Phase 4 · registry result, not featured evidence 7.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 4.3% NCT02354235 · Phase 3 · registry result, not featured evidence · combination 9.2%300 mg NCT01809327 · Phase 3 · registry result, not featured evidence 11%100 mg NCT01809327 · Phase 3 · registry result, not featured evidence 10.5%Canagliflozin 300 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 5.1%Canagliflozin 100 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 24.6%300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence 23.7%100 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 5.3%300 mg NCT01381900 · Phase 3 · registry result, not featured evidence 4%100 mg NCT01381900 · Phase 3 · registry result, not featured evidence 7.9%300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence 16.7%100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence 11.4%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 8%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 12%300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence 12.5%100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence 17.3%300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence 17.8%100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 32.6%300 mg NCT01137812 · Phase 3 · registry result, not featured evidence 14%150 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 8.6%50 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 12.5%300 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 7.8%100 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 10.9%300 mg twice daily NCT00642278 · Phase 2 · registry result, not featured evidence 13.8%200 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 7.8%50 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 6.7%Canagliflozin NCT02324842 · Phase na · registry result, not featured evidence 13.3%Canagliflozin Plus Liraglutide NCT02324842 · Phase na · registry result, not featured evidence · combination | 23.7%10 mgk NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 show 40 more results23.2%25 mg NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 8%10mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 3.7%10mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 8.7%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 17.5%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 8.4%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 15.9%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 —10 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 —25 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 6.2%10 mg NCT04531462 · Phase 4 · registry result, not featured evidence —10 mg NCT04531462 · Phase 4 · registry result, not featured evidence 11.2%10 mg NCT02589639 · Phase 4 · registry result, not featured evidence 4.4%25 mg NCT02589639 · Phase 4 · registry result, not featured evidence 9.4%10 mg NCT02589626 · Phase 4 · registry result, not featured evidence 6.1%25 mg NCT02589626 · Phase 4 · registry result, not featured evidence —25mg NCT02589626 · Phase 4 · registry result, not featured evidence 2.7%10 mg NCT04233801 · Phase 3 · registry result, not featured evidence 5.5%25 mg NCT04233801 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 18.1%10 mg-25 mg NCT02182830 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 7%10 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 10.2%25 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 7.5%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 5.3%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 10%12.5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 9.9%5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 7.7%5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 0%10 mg NCT01947855 · Phase 3 · registry result, not featured evidence 0%25 mg NCT01947855 · Phase 3 · registry result, not featured evidence —Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence —Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination 12.1%Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence —25 mg NCT02632747 · Phase 2 · registry result, not featured evidence 8.6%10 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 6%25 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 6.4%12.5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence 7.8%5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —300 mgj NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 72 more results—100 mg NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 9.5%300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.2%100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 —300 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 —100 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 —100 mg NCT02065791 · Phase 3 — NCT02964585 · Phase 4 · registry result, not featured evidence —300 mg NCT03267576 · Phase 4 · registry result, not featured evidence — NCT02920918 · Phase 4 · registry result, not featured evidence — NCT01989754 · Phase 4 · registry result, not featured evidence 5.3% NCT02622113 · Phase 4 · registry result, not featured evidence · combination 5.6% NCT02227849 · Phase 4 · registry result, not featured evidence · combination 0.9% NCT02025907 · Phase 4 · registry result, not featured evidence 1.3% NCT02220920 · Phase 4 · registry result, not featured evidence · combination 0%300 mg NCT01939496 · Phase 4 · registry result, not featured evidence 0%100 mg NCT01939496 · Phase 4 · registry result, not featured evidence 4.6% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 2.9% NCT02354235 · Phase 3 · registry result, not featured evidence · combination 2.9%300 mg NCT01809327 · Phase 3 · registry result, not featured evidence 1.3%100 mg NCT01809327 · Phase 3 · registry result, not featured evidence 3.4%Canagliflozin 300 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 1.7%Canagliflozin 100 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 9.7%300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence 3.7%100 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 3.1%300 mg NCT01381900 · Phase 3 · registry result, not featured evidence 2.7%100 mg NCT01381900 · Phase 3 · registry result, not featured evidence 2.2%300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence 4.4%100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence 3.5%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 0.9%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 1.6%300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence 4.9%100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence 5.1%300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence 5.1%100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —300 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence —100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 5.6%300 mg NCT01137812 · Phase 3 · registry result, not featured evidence 7.5%150 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 1.1%50 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 3.1%300 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 4.7%100 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 3.1%300 mg twice daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.5%200 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.6%50 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence —Canagliflozin NCT02324842 · Phase na · registry result, not featured evidence —Canagliflozin Plus Liraglutide NCT02324842 · Phase na · registry result, not featured evidence · combination | 11.4%10 mgk NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 show 40 more results11.6%25 mg NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 2.7%10mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.9%10mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 3.2%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.9%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.3%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 1.4%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 —10 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 —25 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 4.6%10 mg NCT04531462 · Phase 4 · registry result, not featured evidence —10 mg NCT04531462 · Phase 4 · registry result, not featured evidence 5.6%10 mg NCT02589639 · Phase 4 · registry result, not featured evidence 3.3%25 mg NCT02589639 · Phase 4 · registry result, not featured evidence 3.1%10 mg NCT02589626 · Phase 4 · registry result, not featured evidence 3%25 mg NCT02589626 · Phase 4 · registry result, not featured evidence —25mg NCT02589626 · Phase 4 · registry result, not featured evidence —10 mg NCT04233801 · Phase 3 · registry result, not featured evidence —25 mg NCT04233801 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination —10 mg-25 mg NCT02182830 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 1.7%10 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 2.4%25 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 0%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 3.5%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 2.9%12.5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 2.3%5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 1.8%5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination —10 mg NCT01947855 · Phase 3 · registry result, not featured evidence —25 mg NCT01947855 · Phase 3 · registry result, not featured evidence —Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence —Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination 4.8%Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence —25 mg NCT02632747 · Phase 2 · registry result, not featured evidence 5.9%10 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 2.3%25 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 2.3%12.5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence 1.8%5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 42.1%300 mgj NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 72 more results41.6%100 mg NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 9.7%300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 5.4%300 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 9.7%100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 5%100 mg NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 5.9%300 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 10.4%100 mg NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 33.5%100 mg NCT02065791 · Phase 3 0% NCT02964585 · Phase 4 · registry result, not featured evidence 0%300 mg NCT03267576 · Phase 4 · registry result, not featured evidence 17.6% NCT02920918 · Phase 4 · registry result, not featured evidence 24.6% NCT01989754 · Phase 4 · registry result, not featured evidence 9.3% NCT02622113 · Phase 4 · registry result, not featured evidence · combination 7% NCT02227849 · Phase 4 · registry result, not featured evidence · combination 1.9% NCT02025907 · Phase 4 · registry result, not featured evidence 4% NCT02220920 · Phase 4 · registry result, not featured evidence · combination 0%300 mg NCT01939496 · Phase 4 · registry result, not featured evidence 0%100 mg NCT01939496 · Phase 4 · registry result, not featured evidence 7.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 1.4% NCT02354235 · Phase 3 · registry result, not featured evidence · combination 2.9%300 mg NCT01809327 · Phase 3 · registry result, not featured evidence 1.7%100 mg NCT01809327 · Phase 3 · registry result, not featured evidence 1.7%Canagliflozin 300 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination 3%Canagliflozin 100 mg + Metformin X NCT01809327 · Phase 3 · registry result, not featured evidence · combination —300 mg NCT01106651 · Phase 3 · registry result, not featured evidence 18.2%300 mg NCT01106651 · Phase 3 · registry result, not featured evidence 3.4%300 mg NCT01106651 · Phase 3 · registry result, not featured evidence —100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 16.6%100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 4.1%100 mg NCT01106651 · Phase 3 · registry result, not featured evidence 1.8%300 mg NCT01381900 · Phase 3 · registry result, not featured evidence 2.2%100 mg NCT01381900 · Phase 3 · registry result, not featured evidence —300 mg NCT01064414 · Phase 3 · registry result, not featured evidence 11.2%300 mg NCT01064414 · Phase 3 · registry result, not featured evidence 23.6%300 mg NCT01064414 · Phase 3 · registry result, not featured evidence —100 mg NCT01064414 · Phase 3 · registry result, not featured evidence 11.1%100 mg NCT01064414 · Phase 3 · registry result, not featured evidence 20%100 mg NCT01064414 · Phase 3 · registry result, not featured evidence —300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 3.5%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence 6.1%300 mg NCT01106690 · Phase 3 · registry result, not featured evidence —100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 2.7%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence 7.1%100 mg NCT01106690 · Phase 3 · registry result, not featured evidence —300 mg NCT01106677 · Phase 3 · registry result, not featured evidence 2.7%300 mg NCT01106677 · Phase 3 · registry result, not featured evidence 3.3%300 mg NCT01106677 · Phase 3 · registry result, not featured evidence —100 mg NCT01106677 · Phase 3 · registry result, not featured evidence 3.3%100 mg NCT01106677 · Phase 3 · registry result, not featured evidence 4.1%100 mg NCT01106677 · Phase 3 · registry result, not featured evidence —300 mg NCT01106625 · Phase 3 · registry result, not featured evidence 3.8%300 mg NCT01106625 · Phase 3 · registry result, not featured evidence 5.1%300 mg NCT01106625 · Phase 3 · registry result, not featured evidence —100 mg NCT01106625 · Phase 3 · registry result, not featured evidence 3.2%100 mg NCT01106625 · Phase 3 · registry result, not featured evidence 4.5%100 mg NCT01106625 · Phase 3 · registry result, not featured evidence 2.3%300 mg NCT01081834 · Phase 3 · registry result, not featured evidence 1%300 mg NCT01081834 · Phase 3 · registry result, not featured evidence 2.5%300 mg NCT01081834 · Phase 3 · registry result, not featured evidence 0%100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 4.1%100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 5.6%100 mg NCT01081834 · Phase 3 · registry result, not featured evidence 6.4%300 mg NCT01137812 · Phase 3 · registry result, not featured evidence 3.2%150 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 0%50 mg Bid NCT01340664 · Phase 2 · registry result, not featured evidence 1.6%300 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.6%100 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.6%300 mg twice daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.5%200 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 1.6%50 mg daily NCT00642278 · Phase 2 · registry result, not featured evidence 6.7%Canagliflozin NCT02324842 · Phase na · registry result, not featured evidence 0%Canagliflozin Plus Liraglutide NCT02324842 · Phase na · registry result, not featured evidence · combination | 37.4%10 mgk NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 show 40 more results39%25 mg NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 4.9%10mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 3.2%10mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 0.5%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 5%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.3%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 1.4%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 5.4%10 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 0%25 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 —10 mg NCT04531462 · Phase 4 · registry result, not featured evidence 12.3%10 mg NCT04531462 · Phase 4 · registry result, not featured evidence 10.5%10 mg NCT02589639 · Phase 4 · registry result, not featured evidence 8.9%25 mg NCT02589639 · Phase 4 · registry result, not featured evidence 6.3%10 mg NCT02589626 · Phase 4 · registry result, not featured evidence —25 mg NCT02589626 · Phase 4 · registry result, not featured evidence 3%25mg NCT02589626 · Phase 4 · registry result, not featured evidence 13.7%10 mg NCT04233801 · Phase 3 · registry result, not featured evidence 9.6%25 mg NCT04233801 · Phase 3 · registry result, not featured evidence 5.2%25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 0.9%10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 3.7%10 mg-25 mg NCT02182830 · Phase 3 · registry result, not featured evidence 3.6%25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 4.5%10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 0.6%10 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 1.8%25 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 3.8%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 1.2%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 3.5%12.5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 1.8%5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 1.2%5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 0%10 mg NCT01947855 · Phase 3 · registry result, not featured evidence 0%25 mg NCT01947855 · Phase 3 · registry result, not featured evidence 6.4%Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence 7.1%Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination —Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence 0%25 mg NCT02632747 · Phase 2 · registry result, not featured evidence 2.3%10 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 0.9%25 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 2.3%12.5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence 3.2%5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 300 mgj hypoglycaemia 14.6% (placebo 12.1%) nasopharyngitis 14.1% (placebo 15.3%) urinary tract infection 11% (placebo 8.9%) NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 59 more results100 mg nasopharyngitis 15.6% (placebo 15.3%) hypoglycaemia 12.5% (placebo 12.1%) upper respiratory tract infection 10.9% (placebo 11.3%) NCT01032629 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 300 mg nasopharyngitis 11.3% diarrhoea 8% upper respiratory tract infection 7.8% NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 300 mg nasopharyngitis 7.6% diarrhoea 6.8% upper respiratory tract infection 5.6% NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 100 mg nasopharyngitis 9.7% urinary tract infection 9.1% upper respiratory tract infection 7.5% NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 100 mg nasopharyngitis 6.8% back pain 6% urinary tract infection 5.4% NCT00968812 · Phase 3 · combination · Type 2 Diabetes · phase 3 300 mg urinary tract infection 29.4% (placebo 4.6%) urinary tract infection 29.4% (placebo 4.6%) nausea 11.8% (placebo 1.1%) NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 100 mg headache 11.9% (placebo 3.4%) headache 11.9% (placebo 3.4%) nasopharyngitis 11.9% (placebo 5.7%) NCT03170518 · Phase 3 · Type 2 Diabetes · phase 3 100 mg hypoglycaemia 9.7% (placebo 10.3%) urinary tract infection 9.2% (placebo 8.4%) hypertension 6.5% (placebo 8.8%) NCT02065791 · Phase 3 300 mg fatigue 3.2% diarrhoea 1.6% discomfort 1.6% NCT03267576 · Phase 4 · registry result, not featured evidence acute kidney injury 17.6% hypotensive event 11.8% arrhythmic events 5.9% NCT02920918 · Phase 4 · registry result, not featured evidence balanoposthitis 3.2% (placebo 0.9%) NCT01989754 · Phase 4 · registry result, not featured evidence blood glucose decreased 40% (placebo 23.9%) hypoglycaemia 38.7% (placebo 32.8%) nasopharyngitis 34.7% (placebo 25.4%) NCT02622113 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 33.8% gastroenteritis 9.9% hypoglycaemia 9.9% NCT02227849 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 5.6% (placebo 5.6%) back pain 2.8% (placebo 0.9%) depression 2.8% (placebo 0%) NCT02025907 · Phase 4 · registry result, not featured evidence blood glucose decreased 26.7% (placebo 16.9%) hypoglycaemia 25.3% (placebo 21.1%) nasopharyngitis 16% (placebo 18.3%) NCT02220920 · Phase 4 · registry result, not featured evidence · combination 300 mg pollakiuria 5.4% (placebo 1.8%) nasopharyngitis 0% (placebo 0%) NCT01939496 · Phase 4 · registry result, not featured evidence 100 mg nasopharyngitis 5.3% (placebo 0%) pollakiuria 1.8% (placebo 1.8%) NCT01939496 · Phase 4 · registry result, not featured evidence nasopharyngitis 30.7% pollakiuria 6.5% constipation 5.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 18.6% (placebo 16.2%) NCT02354235 · Phase 3 · registry result, not featured evidence · combination 300 mg nasopharyngitis 3.8% upper respiratory tract infection 2.5% back pain 2.1% NCT01809327 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 3.8% glomerular filtration rate decreased 2.5% influenza 2.5% NCT01809327 · Phase 3 · registry result, not featured evidence diarrhoea 4.2% headache 3% influenza 3% NCT01809327 · Phase 3 · registry result, not featured evidence · combination diarrhoea 4.2% headache 3.8% influenza 3.4% NCT01809327 · Phase 3 · registry result, not featured evidence · combination 300 mg nasopharyngitis 18.6% (placebo 15.2%) hypoglycaemia 15.3% (placebo 19.8%) urinary tract infection 14.8% (placebo 8.9%) NCT01106651 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 9.7% (placebo 19.8%) nasopharyngitis 8.1% (placebo 15.2%) urinary tract infection 7.2% (placebo 8.9%) NCT01106651 · Phase 3 · registry result, not featured evidence 100 mg nasopharyngitis 18.7% (placebo 15.2%) hypoglycaemia 15.4% (placebo 19.8%) urinary tract infection 13.3% (placebo 8.9%) NCT01106651 · Phase 3 · registry result, not featured evidence 100 mg hypoglycaemia 10.4% (placebo 19.8%) nasopharyngitis 9.5% (placebo 15.2%) influenza 5.8% (placebo 7.6%) NCT01106651 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 7.5% (placebo 4%) upper respiratory tract infection 5.7% (placebo 6.2%) NCT01381900 · Phase 3 · registry result, not featured evidence 100 mg hypoglycaemia 9% (placebo 4%) upper respiratory tract infection 3.1% (placebo 6.2%) NCT01381900 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 11.2% (placebo 4.4%) nasopharyngitis 7.9% (placebo 11.1%) urinary tract infection 7.9% (placebo 5.6%) NCT01064414 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 22.5% (placebo 4.4%) urinary tract infection 13.5% (placebo 5.6%) nasopharyngitis 10.1% (placebo 11.1%) NCT01064414 · Phase 3 · registry result, not featured evidence 100 mg hypoglycaemia 14.4% (placebo 4.4%) arthralgia 4.4% (placebo 2.2%) bronchitis 4.4% (placebo 3.3%) NCT01064414 · Phase 3 · registry result, not featured evidence 100 mg hypoglycaemia 20% (placebo 4.4%) arthralgia 5.6% (placebo 2.2%) bronchitis 5.6% (placebo 3.3%) NCT01064414 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 9.6% (placebo 5.2%) pollakiuria 6.1% (placebo 0.9%) arthralgia 5.3% (placebo 1.7%) NCT01106690 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 13.2% (placebo 5.2%) arthralgia 7.9% (placebo 1.7%) urinary tract infection 7.9% (placebo 5.2%) NCT01106690 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 8% (placebo 6.1%) back pain 7.1% (placebo 2.6%) nasopharyngitis 5.3% (placebo 5.2%) NCT01106690 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 12.4% (placebo 6.1%) nasopharyngitis 9.7% (placebo 5.2%) back pain 8.8% (placebo 2.6%) NCT01106690 · Phase 3 · registry result, not featured evidence 300 mg diarrhoea 4.9% upper respiratory tract infection 4.9% urinary tract infection 3.5% NCT01106677 · Phase 3 · registry result, not featured evidence 300 mg diarrhoea 6.3% upper respiratory tract infection 6.3% urinary tract infection 4.6% NCT01106677 · Phase 3 · registry result, not featured evidence 100 mg pollakiuria 5.7% urinary tract infection 4.9% nasopharyngitis 4.1% NCT01106677 · Phase 3 · registry result, not featured evidence 100 mg urinary tract infection 7.3% pollakiuria 5.7% headache 5.2% NCT01106677 · Phase 3 · registry result, not featured evidence 300 mg diarrhoea 6.4% (placebo 3.2%) hypoglycaemia 5.8% (placebo 3.8%) nasopharyngitis 5.1% (placebo 2.6%) NCT01106625 · Phase 3 · registry result, not featured evidence 300 mg diarrhoea 7.1% (placebo 3.2%) hypoglycaemia 7.1% (placebo 3.8%) nasopharyngitis 5.8% (placebo 2.6%) NCT01106625 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 10.8% (placebo 6.4%) hypoglycaemia 7% (placebo 3.8%) urinary tract infection 5.7% (placebo 5.1%) NCT01106625 · Phase 3 · registry result, not featured evidence 100 mg upper respiratory tract infection 13.4% (placebo 6.4%) hypoglycaemia 8.3% (placebo 3.8%) urinary tract infection 7.6% (placebo 5.1%) NCT01106625 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 6.8% (placebo 5.2%) pain in extremity 6.8% (placebo 0%) urinary tract infection 4.5% (placebo 4.2%) NCT01081834 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 8.1% (placebo 5.2%) back pain 6.1% (placebo 3.1%) headache 6.1% (placebo 3.6%) NCT01081834 · Phase 3 · registry result, not featured evidence 300 mg nasopharyngitis 10.2% (placebo 5.2%) headache 8.6% (placebo 3.6%) back pain 7.6% (placebo 3.1%) NCT01081834 · Phase 3 · registry result, not featured evidence 100 mg urinary tract infection 6.4% (placebo 4.2%) nasopharyngitis 4.3% (placebo 5.2%) pain in extremity 2.1% (placebo 0%) NCT01081834 · Phase 3 · registry result, not featured evidence 100 mg headache 7.2% (placebo 3.6%) urinary tract infection 7.2% (placebo 4.2%) nasopharyngitis 5.1% (placebo 5.2%) NCT01081834 · Phase 3 · registry result, not featured evidence 100 mg headache 9.7% (placebo 3.6%) urinary tract infection 8.2% (placebo 4.2%) nasopharyngitis 7.2% (placebo 5.2%) NCT01081834 · Phase 3 · registry result, not featured evidence 300 mg hypoglycaemia 17.5% nasopharyngitis 8.8% upper respiratory tract infection 8.8% NCT01137812 · Phase 3 · registry result, not featured evidence 300 mg daily headache 4.7% (placebo 3.1%) nausea 4.7% (placebo 0%) abdominal pain upper 3.1% (placebo 1.5%) NCT00642278 · Phase 2 · registry result, not featured evidence 100 mg daily headache 7.8% (placebo 3.1%) urinary tract infection 3.1% (placebo 6.2%) vulvovaginal mycotic infection 3.1% (placebo 0%) NCT00642278 · Phase 2 · registry result, not featured evidence 300 mg twice daily nausea 7.8% (placebo 0%) abdominal pain upper 6.3% (placebo 1.5%) urinary tract infection 4.7% (placebo 6.2%) NCT00642278 · Phase 2 · registry result, not featured evidence 200 mg daily urinary tract infection 9.2% (placebo 6.2%) vulvovaginal mycotic infection 6.2% (placebo 0%) headache 3.1% (placebo 3.1%) NCT00642278 · Phase 2 · registry result, not featured evidence 50 mg daily nasopharyngitis 7.8% (placebo 3.1%) vulvovaginal mycotic infection 6.3% (placebo 0%) nausea 4.7% (placebo 0%) NCT00642278 · Phase 2 · registry result, not featured evidence urinary frequency increased 86.7% dry mouth 26.7% light-headedness/dizziness 26.7% NCT02324842 · Phase na · registry result, not featured evidence nausea 53.3% dry mouth 40% constipation 33.3% NCT02324842 · Phase na · registry result, not featured evidence · combination | 10 mgk hypoglycaemia 29.6% (placebo 29.4%) urinary tract infection 14.5% (placebo 14.7%) hyperglycaemia 9.3% (placebo 18.1%) NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 show 37 more results25 mg hypoglycaemia 28.7% (placebo 29.4%) urinary tract infection 14.4% (placebo 14.7%) nasopharyngitis 9.4% (placebo 9.3%) NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 10mg hypoglycaemia 15.6% (placebo 9.8%) urinary tract infection 9.4% (placebo 6.7%) nasopharyngitis 8% (placebo 4.9%) NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 10mg nasopharyngitis 5.5% (placebo 4.9%) urinary tract infection 4.1% (placebo 6.7%) hyperglycaemia 2.3% (placebo 12.4%) NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 25mg hypoglycaemia 12.9% (placebo 9.8%) urinary tract infection 6.9% (placebo 6.7%) nasopharyngitis 6% (placebo 4.9%) NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 25mg hypoglycaemia 8.9% (placebo 9.8%) hyperglycaemia 7.9% (placebo 12.4%) nasopharyngitis 5% (placebo 4.9%) NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 25mg nasopharyngitis 7% (placebo 4.9%) upper respiratory tract infections 4.2% (placebo 5.3%) urinary tract infection 4.2% (placebo 6.7%) NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 25mg nasopharyngitis 7.2% (placebo 4.9%) urinary tract infection 7.2% (placebo 6.7%) diarrhoea 5.8% (placebo 0%) NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 10 mg headache 16.2% (placebo 15.5%) hypoglycaemia 16.2% (placebo 12.1%) vitamin d deficiency 13.5% (placebo 13.8%) NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 25 mg hypoglycaemia 17.2% (placebo 12.1%) blood ketone body increased 10.3% (placebo 3.4%) headache 10.3% (placebo 15.5%) NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 10 mg constipation 10.8% (placebo 4.7%) pyrexia 6.2% (placebo 4.7%) nasopharyngitis 4.6% (placebo 6.3%) NCT04531462 · Phase 4 · registry result, not featured evidence 10 mg nasopharyngitis 34.9% (placebo 31.1%) hypoglycaemia 27.9% (placebo 21.1%) pollakiuria 10.5% (placebo 2.2%) NCT02589639 · Phase 4 · registry result, not featured evidence 25 mg hypoglycaemia 27.8% (placebo 21.1%) nasopharyngitis 26.7% (placebo 31.1%) pollakiuria 10% (placebo 2.2%) NCT02589639 · Phase 4 · registry result, not featured evidence 10 mg viral upper respiratory tract infection 31.3% fall 3.1% influenza 0% NCT02589626 · Phase 4 · registry result, not featured evidence 25mg viral upper respiratory tract infection 33.3% influenza 9.1% fall 6.1% NCT02589626 · Phase 4 · registry result, not featured evidence 10 mg hypoglycaemia 20.5% (placebo 15.1%) urinary tract infection 8.2% (placebo 13.7%) hyperlipidaemia 5.5% (placebo 2.7%) NCT04233801 · Phase 3 · registry result, not featured evidence 25 mg hypoglycaemia 15.1% (placebo 15.1%) urinary tract infection 8.2% (placebo 13.7%) hyperlipidaemia 5.5% (placebo 2.7%) NCT04233801 · Phase 3 · registry result, not featured evidence 25 mg + 5 mg viral upper respiratory tract infection 26.7% (placebo 22.2%) blood ketone body increased 13.8% (placebo 10.2%) back pain 6% (placebo 2.8%) NCT02489968 · Phase 3 · registry result, not featured evidence · combination 10 mg + 5 mg viral upper respiratory tract infection 15% (placebo 22.2%) back pain 2.8% (placebo 2.8%) contusion 2.8% (placebo 0.9%) NCT02489968 · Phase 3 · registry result, not featured evidence · combination 10 mg-25 mg lipase increased 7.5% (placebo 3.9%) cough 6.3% (placebo 1.3%) upper respiratory tract infection 2.5% (placebo 5.2%) NCT02182830 · Phase 3 · registry result, not featured evidence 25 mg + 5 mg nasopharyngitis 3.6% (placebo 7.3%) lipase increased 2.7% (placebo 5.5%) urinary tract infection 2.7% (placebo 6.4%) NCT01734785 · Phase 3 · registry result, not featured evidence · combination 10 mg + 5 mg urinary tract infection 7.1% (placebo 6.4%) nasopharyngitis 4.5% (placebo 7.3%) lipase increased 3.6% (placebo 5.5%) NCT01734785 · Phase 3 · registry result, not featured evidence · combination 10 mg qd dyslipidaemia 8.7% urinary tract infection 7% upper respiratory tract infection 2.9% NCT01719003 · Phase 3 · registry result, not featured evidence 25 mg qd urinary tract infection 7.8% dyslipidaemia 6.6% upper respiratory tract infection 4.2% NCT01719003 · Phase 3 · registry result, not featured evidence 12.5 mg Bid + 1000 mg Bid diarrhoea 7.5% dizziness 5.7% gastritis 5.7% NCT01719003 · Phase 3 · registry result, not featured evidence · combination 12.5 mg Bid + 1000 mg Bid urinary tract infection 10.6% diarrhoea 7.1% dyslipidaemia 4.7% NCT01719003 · Phase 3 · registry result, not featured evidence · combination 12.5 mg Bid + 500 mg Bid urinary tract infection 10% dizziness 5.3% diarrhoea 3.5% NCT01719003 · Phase 3 · registry result, not featured evidence · combination 5 mg Bid + 1000 mg Bid urinary tract infection 7% dyslipidaemia 4.7% upper respiratory tract infection 4.7% NCT01719003 · Phase 3 · registry result, not featured evidence · combination 5 mg Bid + 500 mg Bid dyslipidaemia 8.9% diarrhoea 5.3% urinary tract infection 5.3% NCT01719003 · Phase 3 · registry result, not featured evidence · combination 10 mg nasopharyngitis 10% (placebo 4.8%) anal inflammation 0% (placebo 0%) bartholinitis 0% (placebo 0%) NCT01947855 · Phase 3 · registry result, not featured evidence 25 mg anal inflammation 5.3% (placebo 0%) bartholinitis 5.3% (placebo 0%) pollakiuria 5.3% (placebo 0%) NCT01947855 · Phase 3 · registry result, not featured evidence nasopharyngitis 4.1% glomerular filtration rate decreased 3.8% hyperkalaemia 3.8% NCT05254002 · Phase 2 · registry result, not featured evidence hyperkalaemia 9.3% glomerular filtration rate decreased 6.3% diarrhoea 3.4% NCT05254002 · Phase 2 · registry result, not featured evidence · combination 25 mg ketosis 19.4% (placebo 3.3%) fatigue 9.7% (placebo 0%) headache 9.7% (placebo 10%) NCT02632747 · Phase 2 · registry result, not featured evidence 10 mg QD urinary tract infection 6.8% (placebo 3.7%) NCT01649297 · Phase 2 · registry result, not featured evidence 25 mg QD urinary tract infection 4.6% (placebo 3.7%) NCT01649297 · Phase 2 · registry result, not featured evidence 12.5 mg BID urinary tract infection 4.6% (placebo 3.7%) NCT01649297 · Phase 2 · registry result, not featured evidence 5 mg BID urinary tract infection 3.7% (placebo 3.7%) NCT01649297 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 4 versus Phase 3.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eAssessment timepoints differ: 6 weeks versus 24 weeks.
- fTrial phases differ: Phase 3 versus Phase 4.
- gAssessment timepoints differ: 26 weeks versus 52 weeks.
- hPopulation context differs: baseline_threshold differs (hba1c<=11, hba1c>=6.5 versus hba1c<=10.5, hba1c>=6.5).
- iAssessment timepoints differ: 52 weeks versus 24 weeks.
- jPopulation comparability has not been reviewed for 65 of these studies.
- kPopulation comparability has not been reviewed for 31 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Canagliflozin
show 1 more result
show 2 more results
show 2 more results
show 33 more results
show 2 more results
+ 31 further endpoints in the CSV export.
Empagliflozin
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 5 more results
show 1 more result
+ 13 further endpoints in the CSV export.
Chronic Kidney Disease
Shared mechanism: SGLT2 · full Chronic Kidney Disease pipeline
Canagliflozin · Invokana
Marketed by Johnson & Johnson and partners
NCT02065791 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial in 4,401 participants with type 2 diabetes and diabetic nephropathy. Canagliflozin significantly lowered the rate of the composite renal/cardiovascular endpoint (kidney failure, doubling of creatinine, or renal/CV death) compared with placebo, with a hazard ratio of 0.70.
Next expected readout: December 2026 · NCT05507892 (registry estimate)
Reported efficacy
Percentage of Participants With 30% Decline in Estimated Glomerular Filtration Rate (eGFR) From Baseline at Week 104: Incidence of 30% eGFR decline at week 104: 18.2% canagliflozin vs 29.5% placebo; intergroup difference (placebo-canagliflozin) 11.3% (95% CI 1.2-21.5, P=0.029) (met)
Result source: NCT03436693
Empagliflozin · Jardiance
Marketed by Boehringer Ingelheim and partners
NCT03594110 · Phase 3 · completed
Patients with chronic kidney disease (6,609) were randomly assigned to empagliflozin 10 mg or matching placebo under double-blind conditions. The primary outcome was a composite of kidney disease progression or cardiovascular death. It was registered for the active trial and again for the whole study, which added up to 2 years of follow-up after the study drug stopped. Empagliflozin reduced the outcome in the active trial (hazard ratio 0.72, 95% CI 0.64 to 0.82, P<0.001) and over the whole study (hazard ratio 0.79, 95% CI 0.72 to 0.87). The figures come from the two published papers (N Engl J Med 2023 and 2025).
Next expected readout: December 2026 · NCT05786443 (registry estimate)
Reported efficacy
Time to first kidney disease progression or cardiovascular death (adjudicated): in the interventional part (up to 1136 days) and over the overall study including post-trial follow-up (up to 1869 days): Primary 1, kidney disease progression or cardiovascular death in the active trial (median 2.0 years): 432/3304 (13.1%) empagliflozin vs 558/3305 (16.9%) placebo; HR 0.72 (95% CI 0.64 to 0.82; P<0.001), met. Primary 2, the same outcome over the active trial plus post-trial follow-up: 865/3304 (26.2%) vs 1001/3305 (30.3%); HR 0.79 (95% CI 0.72 to 0.87), met. (met)
Result source: NCT03594110
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Canagliflozin | Empagliflozin |
|---|---|---|
| Kidney composite outcome | —Not reported | 6.1% vs 8.1%−2 vs placeboNCT035941101 other result
|
| UACR, % change | 0.6% vs 1.2%−0.6 vs placeboNCT03436693 | -39.1% vs -2.6%−36.5 vs placeboNCT051828405 other results
|
| eGFR slope | —Not reported | —Not posted · NCT05373680 |
| Haemoglobin, change | —Not reported | —Not posted · NCT05373680 |
Kidney composite outcome
- Canagliflozin
- —Not reported
- Empagliflozin
- 6.1% vs 8.1%−2 vs placeboNCT03594110
1 other result
- 7.5% vs 8.9% NCT03594110
UACR, % change
- Canagliflozin
- 0.6% vs 1.2%−0.6 vs placeboNCT03436693
- Empagliflozin
- -39.1% vs -2.6%−36.5 vs placeboNCT05182840
5 other results
- -36.6% vs -2.6% NCT05182840
- -22.4% vs -2.6% NCT05182840
- -19% vs -10.6% NCT05182840
- -45.9% vs -10.6% NCT05182840
- -40.3% vs -10.6% NCT05182840
eGFR slope
- Canagliflozin
- —Not reported
- Empagliflozin
- —Not posted · NCT05373680
Haemoglobin, change
- Canagliflozin
- —Not reported
- Empagliflozin
- —Not posted · NCT05373680
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Canagliflozin: 4 of 4 rows · Empagliflozin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Canagliflozin | Empagliflozin |
|---|---|---|
| Dropout rate | 0.7%100 mga NCT02065791 · Phase 3 show 1 more result19.5%100mg NCT03436693 · Phase 3 | 22.9%10 mga NCT03594110 · Phase 3 show 9 more results—Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence —Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination 12.1%Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence —10 mg NCT05182840 · Phase 2 · registry result, not featured evidence —20 mg NCT05182840 · Phase 2 · registry result, not featured evidence —10 mg + 10 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —10 mg + 20 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —10 mg + 3 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —3 mg NCT05182840 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —100 mga NCT02065791 · Phase 3 show 1 more result14.3%100mg NCT03436693 · Phase 3 | 7.2%10 mga NCT03594110 · Phase 3 show 9 more results—Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence —Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination 4.8%Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence —10 mg NCT05182840 · Phase 2 · registry result, not featured evidence —20 mg NCT05182840 · Phase 2 · registry result, not featured evidence —10 mg + 10 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —10 mg + 20 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —10 mg + 3 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —3 mg NCT05182840 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 33.5%100 mga NCT02065791 · Phase 3 show 1 more result27.9%100mg NCT03436693 · Phase 3 | 33%10 mga NCT03594110 · Phase 3 show 9 more results6.4%Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence 7.1%Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination —Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence 5.6%10 mg NCT05182840 · Phase 2 · registry result, not featured evidence 8.3%20 mg NCT05182840 · Phase 2 · registry result, not featured evidence 9.6%10 mg + 10 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination 6.8%10 mg + 20 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination 5.3%10 mg + 3 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination 4.3%3 mg NCT05182840 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 100 mga hypoglycaemia 9.7% (placebo 10.3%) urinary tract infection 9.2% (placebo 8.4%) hypertension 6.5% (placebo 8.8%) NCT02065791 · Phase 3 show 1 more result100mg nasopharyngitis 35.1% (placebo 37%) hypoglycaemia 21.4% (placebo 20.8%) blood glucose decreased 17.5% (placebo 14.9%) NCT03436693 · Phase 3 | show 8 more resultsnasopharyngitis 4.1% glomerular filtration rate decreased 3.8% hyperkalaemia 3.8% NCT05254002 · Phase 2 · registry result, not featured evidence hyperkalaemia 9.3% glomerular filtration rate decreased 6.3% diarrhoea 3.4% NCT05254002 · Phase 2 · registry result, not featured evidence · combination 10 mg glomerular filtration rate decreased 9.9% (placebo 4.1%) hyperkalaemia 9.9% (placebo 5.5%) cortisol decreased 5.6% (placebo 0%) NCT05182840 · Phase 2 · registry result, not featured evidence 20 mg hyperkalaemia 23.6% (placebo 5.5%) glomerular filtration rate decreased 8.3% (placebo 4.1%) upper respiratory tract infection 4.2% (placebo 2.7%) NCT05182840 · Phase 2 · registry result, not featured evidence 10 mg + 10 mg hyperkalaemia 15.1% (placebo 5.5%) glomerular filtration rate decreased 11% (placebo 4.1%) hypotension 5.5% (placebo 0%) NCT05182840 · Phase 2 · registry result, not featured evidence · combination 10 mg + 20 mg glomerular filtration rate decreased 9.5% (placebo 4.1%) hyperkalaemia 9.5% (placebo 5.5%) upper respiratory tract infection 5.4% (placebo 2.7%) NCT05182840 · Phase 2 · registry result, not featured evidence · combination 10 mg + 3 mg hyperkalaemia 6.6% (placebo 5.5%) glomerular filtration rate decreased 5.3% (placebo 4.1%) cortisol decreased 2.6% (placebo 0%) NCT05182840 · Phase 2 · registry result, not featured evidence · combination 3 mg hyperkalaemia 11.4% (placebo 5.5%) cortisol decreased 4.3% (placebo 0%) upper respiratory tract infection 2.9% (placebo 2.7%) NCT05182840 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Canagliflozin
Empagliflozin
show 1 more result
show 1 more result
show 2 more results
show 5 more results
show 23 more results
+ 1 further endpoint in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Canagliflozin's landscape · Empagliflozin's landscape